Fennec Pharmaceuticals (FENC) Corporate presentation summary

Transforming cancer care with PEDMARK®

• PEDMARK® is the first and only FDA-approved therapy for cisplatin-induced ototoxicity, endorsed in NCCN guidelines for AYA cancer patients.

• Robust IP protection ensures no generic entry in the U.S. until 2033, with 10-year pediatric use marketing authorization in Europe.

• Global expansion includes partnerships in Europe, Japan, Turkey, and GCC countries.

• Six consecutive quarters of revenue growth reflect commercial momentum.

The burden of cisplatin-induced hearing loss

• Cisplatin is essential in treating various cancers but causes irreversible hearing loss in 60–90% of patients.

• Hearing loss can begin after just one or two cycles and may worsen years after therapy.

• Quality of life is significantly reduced, impacting speech, learning, social development, and career potential.

• Lifetime costs for early-onset severe hearing loss can exceed $1 million, with major productivity and educational impacts.

PEDMARK®: Clinical value and guidelines

• PEDMARK® reduces the risk of hearing loss without compromising cancer treatment efficacy, with ~50% reduction in hearing loss.

• Only approved therapy in the U.S. for pediatric patients ≥1 month with localized, non-metastatic solid tumors.

• NCCN guidelines recommend PEDMARK® as a Category 2A option for AYA patients.

• Proven safety profile with manageable side effects; not indicated for metastatic cancers or infants under 1 month.